pharma QA – Page 46 – Pharma.Tips

Potency OOS after equipment cleaning: FDA/EMA investigation expectations

Analyzing Potency Out-of-Specification Events Post-Equipment Cleaning: An Examination of FDA and EMA Expectations In the highly regulated environment of pharmaceutical manufacturing, any deviation from potency specifications can trigger extensive investigations.…

Residual Solvent Oos in transdermal patch manufacturing: process parameter review and validation impact

Investigating Residual Solvent OOS in Transdermal Patch Production: A Guide to Process Evaluation The occurrence of out-of-specification (OOS) results related to residual solvents in transdermal patch manufacturing represents a critical…

Finished product microbial limits failure during recall risk assessment: FDA-compliant investigation flow and batch disposition decision tree

Conducting an FDA-Compliant Investigation for Finished Product Microbial Limits Failure during Recall Risk Assessment Finished product microbial limits failures pose significant risks during recall assessments in the pharmaceutical sector. These…

Cross-contamination risk after equipment cleaning: FDA/EMA investigation expectations

“`html Understanding Cross-Contamination Risks Post-Equipment Cleaning: Effective Investigation Strategies Cross-contamination risk after equipment cleaning poses significant challenges in pharmaceutical manufacturing, particularly within oncology product lines. When cleaning protocols fail, contamination…

Delivered Dose Uniformity Failure during method transfer: device qualification and assembly controls

Understanding Delivered Dose Uniformity Failures During Method Transfers in Pharmaceutical Manufacturing In the realm of pharmaceutical manufacturing, delivered dose uniformity (DDU) is a critical quality attribute, especially pertinent to inhalation…

Finished product CCIT failure during CPV annual product review: stability strategy adjustments and packaging risk mitigation steps

Addressing CCIT Failures in Finished Products During CPV Annual Reviews Failures in Container Closure Integrity Testing (CCIT) during the Continuous Process Verification (CPV) annual product review can present significant compliance…

Assay drift in oncology manufacturing: FDA/EMA investigation expectations

Understanding and Investigating Assay Drift in Oncology Manufacturing Assay drift in oncology manufacturing can pose significant challenges to quality control and regulatory compliance, potentially affecting product efficacy and patient safety.…

Apsd Oos during method transfer: method variability vs true product failure assessment

Assessing Apsd Oos during Method Transfer: Identifying Methods Variability or True Product Failure Pharmaceutical manufacturing is a process that demands precision and compliance with regulatory standards. One common challenge faced…

Finished product viscosity drift during recall risk assessment: manufacturing vs lab root cause mapping and required evidence

Understanding Viscosity Drift in Finished Products: An In-Depth Investigation for Manufacturing and Laboratory Root Cause Analysis In pharmaceutical manufacturing, finished product viscosity is a critical quality attribute that can impact…

Potency OOS during stability pull: risk assessment for patient safety

Understanding Potency OOS During Stability Evaluation: A Comprehensive Investigation Approach During routine stability assessments, unexpected observations related to potency can create significant challenges in ensuring product quality and patient safety.…

Cascade Impactor Setup Error after device supplier change: FDA/MHRA investigation and corrective actions

Cascade Impactor Setup Error Following Device Supplier Change: An Investigative Approach In the world of pharmaceutical manufacturing, the smallest changes can lead to significant deviations. This article addresses the investigation…

Finished product nitrosamine risk assessment gap after method transfer to a new QC lab: risk assessment for patient impact and field alert / recall triggers

Assessing Risks from Nitrosamines in Finished Products Post Method Transfer to a New QC Laboratory The pharmaceutical industry faces stringent regulatory expectations, particularly concerning the presence of nitrosamines in finished…